<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426618</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-514</org_study_id>
    <nct_id>NCT03426618</nct_id>
  </id_info>
  <brief_title>A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Real-World Observational Study for the Safety and Efficacy of Baraclude (Entecavir) in Korean Pediatric (Aged 2-16 Years) Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a local, prospective observational study (regulatory post marketing surveillance) to
      access the safety and effectiveness of Baraclude in Korean pediatric patients with chronic
      HBV infection who are between the ages of 2 and less than 16 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">December 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants who achieved a virologic response</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Measured by reduction in hepatitis B virus DNA to &lt;300 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean log reduction in hepititis B virus DNA</measure>
    <time_frame>Baseline to Weeks 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness</measure>
    <time_frame>Baseline and Week 48 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with resistance to Baraclude</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with virologic relapse in participants</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Viral load of less than or equal to 300 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with virologic Relapse in participants</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Viral load greater than 10,000 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who were HBeAg seroconverted at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who had HBeAg loss at week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who were HBsAg seroconverted at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who had HBsAg loss at week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with normalization of serum ALT at week 12</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Normalization is measured as less than or equal to 1 X the upper limit of normal of serum ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with normalization of serum ALT at week 24</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Normalization is measured as less than or equal to 1 X the upper limit of normal of serum ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with normalization of serum ALT at week 48</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>Normalization is measured as less than or equal to 1 X the upper limit of normal of serum ALT</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Pediatric participants with Hepatitis B Virus (HBV)</arm_group_label>
    <description>All participants who received at least 1 dose of Baraclude.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional</description>
    <arm_group_label>Pediatric participants with Hepatitis B Virus (HBV)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be enrolled with chronic hepatitis B virus (CHB)between the ages of 2 and
        less than 16 years and who will begin treatment with Baraclude.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  2 to &lt; 16 years of age

          -  Patients with chronic hepatitis B infection, eligible for treatment with Baraclude as
             indicated in the locally approved prescribing information

        Exclusion Criteria:

          -  Off-label use of the approved label in Baraclude pediatric indication

          -  Patients with a contraindication for the use of Baraclude as described in the locally
             approved prescribing information

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <phone>please email</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

